Foresee Pharma enters into license and distribution agreement with Megapharm

Taiwan and US based biopharmaceutical company, Foresee pharmaceutical Co., Ltd. ventures into an exclusive license and distribution agreement with an Israel based biopharmaceutical company, Megapharm who specialises in oncology and urology. The agreement entails Forsee’s FP-001 program and LMIS (Leuprolide Mesylate Injectable Suspension’s commercialisation in Israel and the Palestine authority. The deal marks the successful launch of the FP-001 Franchise in Israel.

Founder and executive Chairman of Foresee stated, “We are enthusiastic and see a high potential in this new collaboration with Megapharm. They are a key specialty pharma player in their region and have deep commercial expertise and experience in oncology and urology. We entrust them in maximizing FP-001 franchise value in this market well known for its innovation and new product launches”

CEO and Founder of Megapharm, Miron Drucker asserted “We are very pleased to have established a partnership with Foresee and look forward to a successful registration and launch of the FP-001 franchise in Israel. The products will provide meaningful advantages and benefits to patients and all medical practice stakeholders.”